Blue Jet Healthcare Limited Total Liabilities
Blue Jet Healthcare Limited total liabilities. Based on the latest financial reports, Blue Jet Healthcare Limited (BLUEJET) has total liabilities worth Rs2.81 Billion INR (≈ $30.42 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BLUEJET defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Blue Jet Healthcare Limited (2020–2026)
Total liabilities of Blue Jet Healthcare Limited from 2020 to 2026. This chart illustrates how Blue Jet Healthcare Limited's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Blue Jet Healthcare Limited to evaluate the company's liquid asset resilience ratio.
Blue Jet Healthcare Limited Competitors by Total Liabilities
The table below lists competitors of Blue Jet Healthcare Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Electric Group Company Limited
F:USR
|
Germany | €247.42 Billion |
|
Piraeus Port Authority S.A
AT:PPA
|
Greece | €226.60 Million |
|
Scandinavian Tobacco Group A/S
CO:STG
|
Denmark | Dkr7.67 Billion |
|
Financial Street Holdings Co Ltd
SHE:000402
|
China | CN¥82.27 Billion |
|
Critical Metals Corp. Ordinary Shares
NASDAQ:CRML
|
USA | $123.42 Million |
|
NWPX Infrastructure, Inc.
NASDAQ:NWPX
|
USA | $233.30 Million |
|
Anhui Andeli Department Store Co Ltd
SHG:603031
|
China | CN¥2.74 Billion |
|
Droneshield Ltd
AU:DRO
|
Australia | AU$38.99 Million |
Liability Composition Analysis (2020–2026)
This chart breaks down Blue Jet Healthcare Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BLUEJET current and non-current assets.
Liquidity & Leverage Metrics
Blue Jet Healthcare Limited Total Liabilities Ratios Explained
Blue Jet Healthcare Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Blue Jet Healthcare Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Blue Jet Healthcare Limited (2020–2026)
The table below shows the annual total liabilities of Blue Jet Healthcare Limited from 2020 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs2.81 Billion ≈ $30.42 Million |
-1.12% |
| 2025-03-31 | Rs2.84 Billion ≈ $30.76 Million |
+33.14% |
| 2024-03-31 | Rs2.14 Billion ≈ $23.10 Million |
+18.30% |
| 2023-03-31 | Rs1.81 Billion ≈ $19.53 Million |
-5.87% |
| 2022-03-31 | Rs1.92 Billion ≈ $20.75 Million |
-2.35% |
| 2021-03-31 | Rs1.96 Billion ≈ $21.25 Million |
+13.79% |
| 2020-03-31 | Rs1.73 Billion ≈ $18.67 Million |
-- |
About Blue Jet Healthcare Limited
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance… Read more